Current Problems in Cancer最新文献

{"title":"Information for Readers","authors":"","doi":"10.1016/S0147-0272(25)00004-2","DOIUrl":"10.1016/S0147-0272(25)00004-2","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"54 ","pages":"Article 101177"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143132476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page","authors":"","doi":"10.1016/S0147-0272(25)00003-0","DOIUrl":"10.1016/S0147-0272(25)00003-0","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"54 ","pages":"Article 101176"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143132475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ophthalmologic toxicities of antineoplastic agents in genitourinary cancers: Mechanisms, management, and clinical implications","authors":"Aditya Mahadevan ,&nbsp;Omid Yazdanpanah ,&nbsp;Vivek Patel ,&nbsp;David J. Benjamin ,&nbsp;Arash Rezazadeh Kalebasty","doi":"10.1016/j.currproblcancer.2024.101171","DOIUrl":"10.1016/j.currproblcancer.2024.101171","url":null,"abstract":"<div><div>Genitourinary cancers affect over 480,000 patients in the United States annually. While promising therapeutic modalities continue to emerge, notably immune checkpoint inhibitors, molecular targeted therapies, antibody-drug conjugates, and radioligand therapies, these treatments are associated with a spectrum of adverse side-effects, including ophthalmologic toxicities. In this review, we cover the most commonly used antineoplastic agents for the kidneys, bladder, urinary tracts, prostate, testis, and penis, detailing mechanism, indication, and recent trials supporting their use. For each category of antineoplastic therapy, we describe the epidemiology, management, and clinical presentation, of common ophthalmologic toxicities stemming from these agents. This review serves to augment awareness and recognition of possible ophthalmologic manifestations resulting from the use of antineoplastic agents in genitourinary malignancy. Early identification of these side effects can hasten ophthalmology referral and ultimately improve visual outcomes in patients experiencing medication-induced ocular toxicities.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"54 ","pages":"Article 101171"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of efficacy and toxicity of chemotherapeutic regimens used as adjuvant and/or neoadjuvant chemotherapy in penile cancer patients","authors":"Usman Dhasthakeer ,&nbsp;Ambika Nand Jha ,&nbsp;Ashok Kumar Gupta","doi":"10.1016/j.currproblcancer.2025.101185","DOIUrl":"10.1016/j.currproblcancer.2025.101185","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the efficacy and toxicity of different chemotherapeutic regimens used as adjuvant or neoadjuvant chemotherapy in penile cancer patients.</div></div><div><h3>Methodology</h3><div>This observational study was carried out at Mahavir Cancer Sansthan &amp; Research Centre (MCSRC), Patna, involving 112 patients who received various chemotherapy regimens: 5-Fluorouracil with Cisplatin (FP), Paclitaxel with Carboplatin (TP₁), Paclitaxel with Cisplatin (TP₂), and Paclitaxel with Ifosfamide and Cisplatin (TIP). Efficacy was assessed based on tumor response after Neoadjuvant Chemotherapy (NACT) using RECIST v1.1, and Disease-Free Survival (DFS) was calculated with the Kaplan-Meier method. Chemotherapy toxicity was evaluated using CTCAE v4.03, and statistical analysis was performed with SPSS v22.</div></div><div><h3>Results</h3><div>The mean age of the penile cancer patients was found to be 53.5 years. The most of the patients comes under stage-IIIb (62 patients – 55.4%). Out of 88 FP received patients, 28 were treated with NACT in which 24 had partial response (PR) and 4 had progressive disease (PD). The objective response rate (ORR) for this group was found to be 85.71%. Out of 21 TP₁ received patients, 9 were treated with NACT in which 6 had CR and 3 had PR, therefore ORR was found to be 100%. Only one Patient received TIP as NACT had PR. The median DFS rate was found to be 6 months for ACT and 7 months for NACT in FP chemotherapy, whereas 10 months was found to be for ACT and NACT of TP₁ combinations. The patients received TP₁ combinations, had more than 6 months of DFS rate. The grade I-III haematological toxicity of anaemia, lymphocytopenia and thrombocytopenia was observed more in FP than TP₁ and TP₂ combinations. The grade I-III non-haematological toxicity was showed for all chemotherapy combinations.</div></div><div><h3>Conclusion</h3><div>Overall, the TP₁ regimen stands out as the most effective and well-tolerated chemotherapy regimen for penile cancer, demonstrating both superior survival outcomes and a more favourable toxicity profile compared to the FP regimen.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"55 ","pages":"Article 101185"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing lung cancer treatment: Introducing PROTAC therapy as a novel paradigm in targeted therapeutics","authors":"Atharva Mahajan ,&nbsp;Gauri Panzade ,&nbsp;Tiyasa Bhuniya ,&nbsp;Purbasha Das ,&nbsp;Bidyabati Bhattacharjee ,&nbsp;Sagnik Das ,&nbsp;Ankita Chowdhury ,&nbsp;Kashmira Chakraborty ,&nbsp;Sudeepta Guha ,&nbsp;Anushka Samant ,&nbsp;Anuvab Dey ,&nbsp;Subhrojyoti Ghosh","doi":"10.1016/j.currproblcancer.2024.101172","DOIUrl":"10.1016/j.currproblcancer.2024.101172","url":null,"abstract":"<div><div>This comprehensive review explores the transformative potential of PROTAC (Proteolysis-Targeting Chimeras) therapy as a groundbreaking approach in the landscape of lung cancer treatment. The introduction provides a succinct overview of current challenges in lung cancer treatment, emphasizing the significance of targeted therapies. Focusing on PROTAC therapy, the article elucidates its mechanism of action, comparing it with traditional targeted therapies and highlighting the key components and design principles of PROTAC molecules. In the context of lung cancer, the review meticulously summarizes preclinical evidence, emphasizing efficacy and specificity gleaned from studies evaluating PROTAC therapy. It delves into the implications of this preclinical data, discussing potential advantages over existing targeted therapies. An update on ongoing clinical trials involving PROTAC therapy for lung cancer offers a snapshot of the current progress, with a summary of key outcomes and advancements in early-phase trials. The mechanistic insights into PROTAC therapy's impact on lung cancer cells are explored, alongside a discussion on potential biomarkers for patient stratification and response prediction. The influence of tumor heterogeneity on PROTAC therapy outcomes is also addressed. Safety and tolerability assessments, encompassing preclinical and clinical studies, are comprehensively evaluated, including a comparative analysis with traditional targeted therapies and strategies to mitigate side effects. Looking forward, the article discusses the future perspectives of PROTAC therapy in lung cancer treatment and addresses ongoing challenges, providing a nuanced exploration of potential combination therapies and synergistic approaches. In conclusion, the review summarizes key findings and insights, underscoring the tremendous potential of PROTAC therapy as a promising and innovative avenue in pursuing more effective lung cancer treatments.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"54 ","pages":"Article 101172"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint expression and therapeutic implications in IDH1-mutant and wild-type glioblastomas","authors":"Avaniyapuram Kannan Murugan ,&nbsp;Siddarth Kannan ,&nbsp;Ali S. Alzahrani","doi":"10.1016/j.currproblcancer.2025.101182","DOIUrl":"10.1016/j.currproblcancer.2025.101182","url":null,"abstract":"<div><div>Programmed cell death protein 1 (<em>PDCD1</em>) and cluster of differentiation 274 (<em>CD274</em>) expression is implicated in escaping tumors from immune surveillance. Immune checkpoint inhibitors show promise in cancer therapy, yet their efficacy in glioblastomas, particularly with <em>IDH1</em> mutations, remains unclear. This study analyzed two independent NGS datasets (n = 577 and n = 153) from TCGA to investigate the expression of <em>PDCD1</em> and <em>CD274</em> in glioblastomas and their relationship with <em>IDH1</em> mutations. We used cBioPortal for mutation analysis, RNA seq for expression analysis, miRDB and miRabel for differential expression of miRNAs, and Kaplan-Meier for survival prediction. We found that 5.4% of glioblastomas harbored <em>IDH1</em> mutations, correlating with improved overall survival (OS) (<em>p</em> = 2.196e-3). Different glioblastoma cohorts showed a diverse <em>IDH1</em> mutational prevalence (4-31%). Despite this, <em>IDH1</em>^Mu was consistently associated with better OS (<em>p</em> = 8.235e-5). Notably, <em>PDCD1</em> and <em>CD274</em> were statistically significantly highly expressed in both <em>IDH1</em>^Wt (<em>p</em> &lt; 0.0001) and <em>IDH1</em>^Mu tumors (<em>p</em> &lt; 0.0001), with higher expression linked to poorer survival outcomes (<em>PDCD1: p</em> = 0.009; <em>CD274: p</em> = 0.02). Differential co-expression analyses revealed distinct gene and miRNA profiles for <em>IDH1</em>^Wt and <em>IDH1</em>^Mu glioblastomas, with specific upregulation of <em>PTEN</em> and downregulation of <em>MUC16</em> in <em>IDH1</em>^Wt, and upregulation of <em>PIK3R1</em> in <em>IDH1</em>^Mu. Additionally, <em>PIK3R1</em> and <em>ITGB2</em> emerged as critical druggable targets. Our findings indicate that <em>PDCD1</em> and <em>CD274</em> are highly expressed irrespective of <em>IDH1</em> mutation statuses, suggesting that glioblastomas could benefit from immunotherapy. Moreover, <em>IDH1</em>^Mu glioblastomas may require a combination of PI3K/AKT/mTOR inhibitors and immunotherapy due to <em>PIK3R1</em> overexpression.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"55 ","pages":"Article 101182"},"PeriodicalIF":2.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of gene therapy approaches for malignant gliomas: A systematic review and meta-analysis","authors":"Elnaz Amanzadeh Jajin,&nbsp;Saeed Oraee-Yazdani,&nbsp;Alireza Zali,&nbsp;Roozbeh Tavanaei","doi":"10.1016/j.currproblcancer.2025.101183","DOIUrl":"10.1016/j.currproblcancer.2025.101183","url":null,"abstract":"<div><h3>Background</h3><div>Malignant gliomas are the most aggressive brain tumors with no certain therapeutic methods. Nowadays, novel treatment methods are introduced for gliomas among which gene therapy is known as a promising and robust method. In this method, genes with key roles in the prevention of cell cycle or induction of cell suicide are transferred to the tumor site using vectors. Viral vectors are the most popular transfer methods, while the liposomes are also used for gene therapy.</div></div><div><h3>Methods</h3><div>This meta-analysis and systematic review was performed based on PRISMA guidelines. We performed a comprehensive search in databases including PubMed, Embase, and clinicaltrial.gov. After processing and filtering the articles, phase 1 clinical trials were chosen for the evaluation of the efficacy and safety of gene therapy for malignant gliomas.</div></div><div><h3>Results</h3><div>The obtained results showed that gene therapy increases overall survival (OS) and progression-free survival (PFS) in two years of follow-up. Subgroup analysis also showed that cytokines exhibit the highest effectiveness compared to suicide genes and oncolytic genes. It was found that gene therapy is more efficient for recurrent gliomas than primary gliomas. The subgroup analysis for vectors revealed that Adenovirus is the most effective for increasing the OS in malignant glioma patients.</div></div><div><h3>Conclusion</h3><div>Gene therapy is an immunotherapy method for malignant gliomas following the standard treatment approach. Considering the effectiveness of gene therapy on the survival of patients, it is hoped that solving related issues with gene therapy will help to increase the OS rate in this malignant disease.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"55 ","pages":"Article 101183"},"PeriodicalIF":2.5,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information for Readers","authors":"","doi":"10.1016/S0147-0272(24)00105-3","DOIUrl":"10.1016/S0147-0272(24)00105-3","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"53 ","pages":"Article 101164"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143162751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page","authors":"","doi":"10.1016/S0147-0272(24)00104-1","DOIUrl":"10.1016/S0147-0272(24)00104-1","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"53 ","pages":"Article 101163"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143162750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary influence on cancer progression: Gut health and genomic profiles","authors":"Yashar Vaziri","doi":"10.1016/j.currproblcancer.2024.101159","DOIUrl":"10.1016/j.currproblcancer.2024.101159","url":null,"abstract":"<div><div>This scholarly review comprehensively examines the connection between dietary habits, gut health, cancer prognosis, and genomic profiles. It emphasizes the crucial role of gut microbiota in mediating genomic changes and oncogenic processes through metabolic derivatives.It advocatеs for pеrsonalizеd nutrition stratеgiеs based on individual microbiomе and gеnomic profilеs and proposеs that customized diеtary intеrvеntions could play a crucial rolе in cancеr prеvеntion thеrapy. Thе article highlights thе influеncе of spеcific nutriеnts and such as diеtary fibеr and polyphеnols found in cеrtain foods and dеmonstrating thеir potеntial to altеr gеnе еxprеssions associatеd with inflammation and tumorigеnеsis. Thе rеviеw citеs rеcеnt studiеs that support thе idеa that diеtary modifications can influеncе gеnе rеgulation and thеrеby potеntially altеring cancеr progrеssion. Nevertheless, it calls for morе rigorous rеsеarch including longitudinal and randomizеd studies, to substantiatе thе еvidеncе nеcеssary for developing diеtary guidеlinеs tailorеd for cancеr patiеnts. Thе rеviеw еmphasizеs thе nееd for a multidisciplinary approach and highlight thе importancе of collaboration across thе fiеlds of nutrition gеnomics microbiology and oncology to improve cancеr trеatmеnts and patiеnt quality of lifе. It posits thе rеviеw as a cornеrstonе for a divеrsе audiеncе within thе scientific and mеdical communitimphasizing thе nеcеssity for ongoing rеsеarch in nutritional gеnomics which it dеpicts as a fiеld full of opportunitiеs to transform cancеr carе.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"54 ","pages":"Article 101159"},"PeriodicalIF":2.5,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}